Publications by authors named "Marc Teitelbaum"
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Lancet Microbe
November 2024
Article Synopsis
- rVSVΔG-ZEBOV-GP is a vaccine that helps protect people from the Ebola virus and is the first one to be officially approved for this purpose.
- This study wanted to see how well a booster shot given 18 months after the first vaccine dose helped keep the immune response strong for a longer time.
- Healthy adults who might be at risk of exposure to Ebola participated in the trial, and the results measured their antibody levels 36 months after the first vaccination to compare those who got the booster with those who did not.
The effects of locally applied zinc chloride (ZnCl ) on early and late-stage parameters of fracture healing were evaluated in a diabetic rat model. Type 1 Diabetes has been shown to negatively impact mechanical parameters of bone as well as biologic markers associated with bone healing. Zinc treatments have been shown to reverse those outcomes in tests of nondiabetic and diabetic animals.
View Article and Find Full Text PDFEfficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
Ann Intern Med
September 2022
Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.
Objective: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.
Design: Double-blind, randomized, placebo-controlled, clinical trial.
Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment.
Objective: To evaluate the a priori hypothesis that bamlanivimab has greater benefit in patients without detectable levels of endogenous neutralizing antibody (nAb) at study entry than in those with antibodies, especially if viral levels are high.
Design: Randomized, placebo-controlled trial.
Background/aims: Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership initiated the Therapeutics for Inpatients with COVID-19. Therapeutics for Inpatients with COVID-19 is a multi-arm, multi-stage platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate antiviral therapeutic agents for adults hospitalized with COVID-19.
View Article and Find Full Text PDFBackground: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.
Methods: In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo.
Background: Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpatients with COVID-19 (TICO). TICO is a multi-arm, multi-stage (MAMS) platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of novel candidate anti-viral therapeutic agents for adults hospitalized with COVID-19.
View Article and Find Full Text PDFZinc is an essential mineral that is required for normal skeletal growth and bone homeostasis. Furthermore, zinc appears to be able to promote bone regeneration. However, the cellular and molecular pathways through which zinc promotes bone growth, homeostasis, and regeneration are poorly understood.
View Article and Find Full Text PDFArticle Synopsis
- A clinical trial was conducted in the Democratic Republic of Congo to evaluate the safety and efficacy of four experimental therapies for Ebola virus disease (EVD) during an outbreak that started in August 2018.
- 681 patients were randomly assigned to receive either ZMapp, remdesivir, MAb114, or REGN-EB3, with the primary endpoint being mortality at 28 days.
- Results indicated MAb114 and REGN-EB3 significantly reduced mortality compared to ZMapp and remdesivir, leading to a recommendation to continue only with these two therapies for the remainder of the trial.